PAKISTAN
In accordance with Section 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 of the Pakistan Stock Exchange Rule Book, Macter International Limited has announced the successful launch of Semaglutide in Pre-Filled Syringe (PFS) and Pre-Filled Multi-Dose Pen (PFP) presentations.
Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, is a cutting-edge biotechnology drug widely used for the management of Type 2 Diabetes Mellitus and increasingly recognized for its efficacy in weight management and metabolic health.
With this latest launch, Macter International has become the only company in Pakistan to offer Semaglutide across all three biotechnology dosage formats — Vials, Pre-Filled Syringes, and Pre-Filled Pens.
This milestone represents a significant step forward in the company’s Biotech portfolio, strengthening its position as a pioneer in delivering advanced and globally competitive therapies to patients in Pakistan.
Macter stated that this achievement reflects its ongoing commitment to improving access to innovative treatments and enhancing the quality of healthcare in the country. – ER News Desk
READ MORE NEWS
Engineering Review | November 16-30, 2026
Engineering Review | November 1-15, 2026
China-Pakistan Agricultural Cooperation Trains 885 Professionals, Supports 15 Startups
Program focuses on AI, seed technology, livestock disease surveillance, genomics and water-efficient farming, with more…
HIMEL Sees Strong Growth Opportunities in Pakistan Amid Rising Energy Demand and Infrastructure Development
HIMEL, a leading provider of reliable and accessible electrical solutions, has reaffirmed its long-term commitment…
HVACR Trends 6.0 Draws 3,283 Visitors to Karachi as ASHRAE President Joins Pakistan’s Cooling Industry
The ASHRAE Pakistan Chapter concluded HVACR Trends 6.0, its sixth conference and exhibition, on 16–17…
From Rock to Reality: Bridging Academia and Industry
The Department of Chemical Engineering at NED University of Engineering & Technology, in collaboration with…

